Study Enrollment

Your details will not be published or shared.

Clinical Trial

PrE0404: A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

The purpose of this study is to see whether the addition of ixazomib to ibrutinib chemotherapy is effective in treating people who have relapsed or refractory mantle cell lymphoma and to examine the side effects assicated with ixazomib in combination with ibrutinib.

Eligibility Criteria

  • Must be 18 years of age or older Must have beenrelapsed or refractory, pathologically proven mantle cell lymphoma. Must have been refractoryto and/or relapsed/progressed after at least 1 prior therapy.

Contact Information

    Joanne Huff, RN

    (706) 721-1206